Navigation Links
Neurocrine Biosciences Reports Second Quarter 2012 Results
Date:7/31/2012

vy uterine bleeding due to such fibroids.

VMAT2 UpdateThe Company is moving its VMAT2 inhibitor, NBI-98854, into Phase IIb clinical trials.  An investigator meeting will be held in early August for a large Phase IIb trial which will begin screening in the third quarter of 2012. This placebo-controlled, double-blind, parallel design, multiple dose, 12 week study will assess six week dosing of NBI-98854, against placebo, followed by six weeks of active treatment with NBI-98854. The study will also incorporate a capsule formulation of NBI-98854. Top-line data from this study is expected in the first quarter of 2013.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 800-862-9098 (US) or 785-424-1051 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at ir@neurocrine.com. A replay of the conference call will be available approximately one hour after the conclusion of the call by dialing 800-695-0671 (US) or 402-220-1397 (International) using the conference ID: NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine-related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, tardive dykinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine B
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
2. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
3. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
4. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
5. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
6. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
7. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
8. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
9. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
10. Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
11. Tanke BioSciences To Host Leading Symposium On Food Safety, June 24-25
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Vital Imaging ™ has ... California, San Diego for a joint study which aims ... (Magnetic Resonance Imaging) with that of a supine Dynawell ... pursuit of improved healthcare by combining cutting edge technology ... extremely valuable tool for evaluating pathological changes in the ...
(Date:5/21/2013)... SoundConnect is pleased to announce the release ... in Canada. Lync is the next generation of ... and organizations to collaborate and communicate much more easily ... the United States. With the progressive rollout of Lync ... Canada, SoundConnect now offers a complete Microsoft Lync solution ...
(Date:5/21/2013)... May 21, 2013 The Formulate Fusion ... solution for sales and marketing teams looking for a fully-functional ... the kit as “everything you’ll need to put together a ... Kit comes with a number of displays and accessories that ... 20 feet by 20 feet in size. These components vary ...
(Date:5/20/2013)... May 20, 2013 , ... Research Service (ARS) in treatment of mastitis ... , Trials to begin in the second half ... technology company Phosphagenics Limited (ASX: POH, OTCQX: ... (USDA) Agricultural Research Service (ARS) to develop and trial ...
Breaking Biology Technology:Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... Elekta, a global leader in radiation,oncology and ... at the 49th Annual Meeting of The American ... reduce,treatment times and increase efficiency. The meeting will ... Los Angeles Convention Center (Los Angeles,California, USA). Elekta ...
... N.J., Oct. 18 NPS,Pharmaceuticals, Inc. (Nasdaq: NPSP ... cash tender offer for any and all of its ... at midnight, New,York City time, on October 17, 2007. ... offer, $171.2 million principal,amount of the notes, representing approximately ...
... Glycominds Ltd., a,biodiagnostics company specializing in glycan biomarkers ... cancer, announced today the,appointment of Dr. Chen Even ... Chen, a board member since 2004, contributes more ... "We are very pleased to elevate Dr. Even ...
Cached Biology Technology:Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 2Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 3Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007 4NPS Pharmaceuticals Announces Results of Tender Offer 2NPS Pharmaceuticals Announces Results of Tender Offer 3Glycominds Appoints Board of Directors Chairman 2Glycominds Appoints Board of Directors Chairman 3
(Date:5/21/2013)... Chicago College of Medicine will study gender differences in how ... source -- and how changes in fat metabolism play a ... grant from the National Heart, Lung and Blood Institute. , ... energy. These changes may play a major role in the ... women, says E. Douglas Lewandowski, director of the UIC Center ...
(Date:5/21/2013)... Where? Copenhagen, Denmark: Bella Center Congress Centre ... , Why? An annual meeting focusing ... manufacturing and installation, drawing on leading experiences from all ... from a record of more than 900 abstracts received ... and oral presentations, more than 460 visual presentation, 55 ...
(Date:5/20/2013)... the antibiotic colistin are also commonly resistant to ... to a study in mBio , the ... Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 ... bacterial attack, could mean that patients with life-threatening ... crippled immune response. Colistin is a last-line drug ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... A new study from The Montreal Neurological Institute and Hospital ... to discover a molecular link between Parkinson,s disease and defects ... published in the prestigious journal Molecular Cell and ... , provides new insight into the mechanisms underlying Parkinson,s disease, ...
... the molecular process that can shut down a marauding, ... who suffer battlefield casualties, heart attacks, strokes, automobile accidents ... the January edition of Molecular Immunology. , The ... of a reaction first observed in the lab by ...
... Diseases (NIAID), part of the National Institutes of Health ... Tulane University for its ongoing efforts to treat and ... threatens hundreds of thousands of people annually in West ... The contract will include collaboration between Tulane; Scripps ...
Cached Biology News:Communication breakdown: what happens to nerve cells in Parkinson's disease 2Communication breakdown: what happens to nerve cells in Parkinson's disease 3Research could lead to way to halt deadly immune response 2Research could lead to way to halt deadly immune response 3Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever 2
Peptide-affinity Purified Polyclonal Antibody to MTR...
Purified anti-eIF-4E...
Purified anti-PXR...
Goat polyclonal to MLH3 ( Abpromise for all tested applications). entrezGeneID: 27030 SwissProtID: Q9UHC1...
Biology Products: